Psychiatr. praxi. 2026;27(2):75-80 | DOI: 10.36290/psy.2026.013

Safe psychopharmacotherapy in older age: a practical approach to polypharmacy and drug interactions

MUDr. Vanda Franková
Psychiatrická nemocnice v Dobřanech

Safe psychopharmacotherapy in older age does not begin with choosing the "gentlest" drug, but with a systematic review of the entire medication regimen, assessment of adherence, targeted somatic evaluation, and definition of the treatment goal. This article summarizes a practical approach to psychopharmacotherapy in geriatric psychiatry, with emphasis on anticholinergic burden, sedation, falls, delirium, hyponatremia, bleeding, and cardiovascular risks. It highlights the importance of psychosocial interventions and the need for individualized treatment in the context of multimorbidity and polypharmacy.

Keywords: older age, psychopharmacotherapy, polypharmacy, drug interactions, geriatric psychiatry.

Accepted: June 10, 2026; Published: July 21, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Franková V. Safe psychopharmacotherapy in older age: a practical approach to polypharmacy and drug interactions. Psychiatr. praxi. 2026;27(2):75-80. doi: 10.36290/psy.2026.013.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Purchase PDF - 60 CZK (2.5 EUR)
    will be unlocked 21.7.2027

    References

    1. American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023;71(7):2052-2081. doi:10.1111/jgs.18372. Go to original source... Go to PubMed...
    2. O'Mahony D, Cherubini A, Renom-Guiteras A, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 3. Eur Geriatr Med. 2023;14(4):625-632. doi:10.1007/s41999-023-00777-y. Go to original source...
    3. World Health Organization. Medication safety in polypharmacy: technical report [Internet]. Geneva: World Health Organization; 2019 [cit. 2026-03-20]. Available from: https://www.who.int/publications/i/item/WHO-UHC-SDS-2019.11.
    4. National Institute for Health and Care Excellence. Multimorbidity: clinical assessment and management. NICE guideline NG56 [Internet]. London: NICE; 2016 [cit. 2026-03-20]. Available from: https://www.nice.org.uk/guidance/ng56.
    5. Státní ústav pro kontrolu léčiv. Databáze léčiv [Internet]. Praha: SÚKL; [cit. 2026-03-20]. Available from: https://prehledy.sukl.cz/.
    6. Gheysens T, Van Den Eede F, De Picker L. The risk of antidepressant-induced hyponatremia: A meta-analysis of antidepressant classes and compounds. Eur Psychiatry. 2024;67(1):e20. doi:10.1192/j.eurpsy.2024.11. Go to original source... Go to PubMed...
    7. Rahman AA, Platt RW, Beradid S, et al. Concomitant use of selective serotonin reuptake inhibitors with oral anticoagulants and risk of major bleeding. JAMA Netw Open. 2024;7(3):e243208. doi:10.1001/jamanetworkopen.2024.3208. Go to original source... Go to PubMed...
    8. Pillinger T, Arumuham A, McCutcheon RA, et al. The effects of antidepressants on cardiometabolic and other physiological parameters: a systematic review and network meta-analysis. Lancet. 2025 Nov 1;406(10515):2063-2077. doi: 10.1016/S0140-6736(25)01293-0. Epub 2025 Oct 21. Go to original source... Go to PubMed...
    9. Dell'osso B, Blasi G, Serafini G, et al. Vortioxetine's cardiovascular profile as a relevant feature for the management of major depressive disorder in comorbidity with organic diseases. Expert Review of Neurotherapeutics. 2026;26(2):175-184. doi:10.1080/14737175.2025.2602193. Go to original source... Go to PubMed...
    10. Bjerre LM, Farrell B, Hogel M, et al. Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia: Evidence-based clinical practice guideline. Can Fam Physician. 2018;64(1):17-27.
    11. Mok PLH, Carr MJ, Guthrie B, et al. Multiple adverse outcomes associated with antipsychotic use in people with dementia: population based matched cohort study. BMJ. 2024;385:e076268. doi:10.1136/bmj-2023-076268. Go to original source... Go to PubMed...
    12. Malone K, Hancox JC. QT interval prolongation and Torsades de Pointes with donepezil, rivastigmine and galantamine. Ther Adv Drug Saf. 2020;11:2042098620942416. doi:10.1177/2042098620942416. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.